Active Stocks : Halcon Resources (NYSE:HK), Concert Pharmaceuticals(NASDAQ:CNCE), Eastman Chemical (NYSE:EMN), KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO), Tech Data Corp. (NASDAQ:TECD)

Technology Stocks News 18

Halcon Resources Corp (NYSE:HK) last released its earnings data on Wednesday, July 30th. The company reported $0.07 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.04 by $0.03. The company had revenue of $327.10 million for the quarter, compared to the consensus estimate of $303.63 million. During the same quarter last year, the company posted $0.04 earnings per share. Halcon Resources Corp’s revenue was up 52.6% compared to the same quarter last year. On average, analysts predict that Halcon Resources Corp will post $0.21 earnings per share for the current fiscal year. Halcon Resources Corp. (NYSE:HK) belongs to Basic Materials sector. Its weekly performance is -1.08%. On last trading day company shares ended up $5.50. Halcon Resources Corp. (NYSE:HK) distance from 50-day simple moving average (SMA50) is -12.12%.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has received a $2m milestone as part of a development and license agreement with Avanir Pharmaceuticals for the clinical progression of AVP-786 in patients with major depressive disorder (MDD). The new drug product, AVP-786, is a combination of deuterium modified dextromethorphan and ultra-low dose quinidine. The payment is result of the initiation of dosing by Avanir in a Phase II clinical trial with AVP-786 for the adjunctive treatment in MDD patients. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) shares moved down -1.54% in last trading session and ended the day at $8.96. CNCE return on assets is -28.10%. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) quarterly performance is -2.61%.

Shares of Eastman Chemical Company (NYSE:EMN) have been given an average rating of “Buy” by the thirteen analysts that are currently covering the stock. Six investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $91.36. On 29 August, Eastman Chemical Co. (NYSE:EMN) shares moved up 0.02% and was closed at $82.47. EMN EPS growth in last 5 year was 26.80%. Eastman Chemical Co. (NYSE:EMN) year to date (YTD) performance is 3.01%.

Drug developer Allakos Inc. has raised $24.5 million toward an upsized goal of a $42 million Series A round. The San Mateo company, founded by veterans of KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO), is developing antibody-based drugs against inflammatory diseases, such as asthma, food allergies and gastrointestinal conditions. It is zeroing in on so-called T-helper cells, a type of white blood cell that is dysregulated in allergic diseases and inflammation. KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) ended the last trading day at $1.53. Company weekly volatility is calculated as 4.80%and price to cash ratio as 0.87. KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) showed a weekly performance of 2.68%.

Tech Data Corp (NASDAQ:TECD) last announced its earnings results on Tuesday, August 26th. The company reported $1.12 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.77 by $0.35. The company had revenue of $6.84 billion for the quarter. During the same quarter last year, the company posted $0.73 earnings per share. Tech Data Corp’s revenue was up 8.1% compared to the same quarter last year. Analysts expect that Tech Data Corp will post $5.06 EPS for the current fiscal year. Tech Data Corp. (NASDAQ:TECD) shares moved up 1.05% in last trading session and ended the day on $67.50. TECD Gross Margin is 5.10% and its return on assets is 2.60%. Tech Data Corp. (NASDAQ:TECD) quarterly performance is 12.63%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone